YCYizhen Chen

Yizhen Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yizhen Chen has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Chuhui Chen

    Department of Endocrinology, Shengli Clinical Medical College of Fujian Medical University, Fuzhou University Affiliated Provincial Hospital , Fuzhou 350000

    1 shared publication
  • Gang Chen

    Fujian Medical University

    1 shared publication
  • Junping Wen

    Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fujian Medical University

    1 shared publication
  • Liang Lin

    Shengli Clinical Medical College, Fujian Medical University, Fuzhou, China

    1 shared publication
  • Shaolin Liu

    Department of Geriatric Medicine, Fujian Key Laboratory of Geriatrics Diseases, Fujian Provincial Center for Geriatrics, Fujian Provincial Hospital Fuzhou University Affiliated Provincial Hospital, School of Medicine, Fuzhou University Fuzhou Fujian China

    1 shared publication
  • Ting Xue

    Center of Health Management, Fujian Provincial Hospital; Shengli Clinical Medical College, Fujian Medical University Fuzhou University Affiliated Provincial Hospital Fuzhou China

    1 shared publication

Latest Publications

  • Open Access

    Metaverse Clinic for Pregnant Women With Subclinical Hypothyroidism: Prospective Randomized Study

    by Yuanyuan Zheng, Yizhen Chen, Yan Chen, Liang Lin, Ting Xue, Chuhui Chen, Junping Wen, Wei Lin, Gang Chen

    Background: Health care is experiencing new opportunities in the emerging digital landscape. The metaverse, a shared virtual space, integrates technologies such as augmented reality, virtual reality, blockchain, and artificial intelligence. It allows users to interact with immersive digital worlds, connect with others, and explore unknowns. While the metaverse is gaining traction across various medical disciplines, its application in thyroid diseases remains unexplored. Subclinical hypothyroidism (SCH) is the most common thyroid disorder during pregnancy and is frequently associated with adverse pregnancy outcomes. Objective: This study aims to evaluate the safety and effectiveness of a metaverse platform in managing SCH during pregnancy. Methods: A randomized controlled trial was conducted at Fujian Provincial Hospital, China, from July 2022 to December 2023. A total of 60 pregnant women diagnosed with SCH were randomly assigned into two groups: the standard group (n=30) and the metaverse group (n=30). Both groups received levothyroxine sodium tablets. Additionally, participants in the metaverse group had access to the metaverse virtual medical consultations and metaverse-based medical games. The primary outcomes were adverse maternal and offspring outcomes, and the secondary outcomes included the neurobehavioral development of offspring and maternal psychological assessments. Results: Of the 30 participants in each group, adverse maternal outcomes were observed in 43% (n=13) of the standard group and 37% (n=11) of the metaverse group (P=.60). The incidence of adverse offspring outcomes was 33% (n=10) in the standard group, compared to 7% (n=2) in the metaverse group (P=.01). The Gesell Development Scale did not show significant differences between the two groups. Notably, the metaverse group demonstrated significantly improved scores on the Self-Rating Depression Scale and the Self-Rating Anxiety Scale scores compared to the standard group (P<.001 and P=.001, respectively). Conclusions: The use of metaverse technology significantly reduced the incidence of adverse offspring outcomes and positively impacted maternal mental health. Maternal adverse outcomes and offspring neurobehavioral development were comparable between the two groups. Trial Registration: Chinese Clinical Trial Registry ChiCTR2300076803; https://www.chictr.org.cn/showproj.html?proj=205905


  • Open Access

    KRAS mutation promotes the colonization of Fusobacterium nucleatum in colorectal cancer by down‐regulating SERTAD4

    by Yizhen Chen, Yuanyuan Zheng, Shaolin Liu

    This study explores and verifies potential molecular targets through which KRAS mutations regulate the colonization of Fusobacterium nucleatum (FN) in colorectal cancer (CRC). This study combined multiple bioinformatics methods and biological assays. Through The Cancer Genome Atlas, Gene Expression Omnibus, Human Protein Atlas, immunohistochemistry, and co‐culture assays, we further confirmed the differential expression of SERTAD4 in CRC. We delved deeper into examining how expression of SERTAD4 is linked with immune cell infiltration and the enrichment of potential pathways. Lastly, through bacterial phenotypic assays, we validated the function of SERTAD4. As a molecule associated with KRAS mutations and FN infection, the expression levels of SERTAD4 were downregulated in CRC. The diagnostic efficacy of SERTAD4 for CRC is not inferior to that of CEA. Low expression of SERTAD4 is associated with poorer overall survival in CRC. Correlation analysis found that increased expression of SERTAD4 is associated with various immune cell infiltrations and immune checkpoint genes. Finally, bacterial adhesion and invasion assays verify that SERTAD4 inhibits the adhesion and invasion abilities of FN in CRC. This study demonstrates that SERTAD4 exerts a protective role in CRC by inhibiting the colonization of FN.